Compare FC Barcelona Fan Token (BAR) vs Bio Protocol (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FC Barcelona Fan Token vs Bio Protocol — how do they compare? FC Barcelona Fan Token trades at Rp4,625 (market cap Rp122,14M, Rp83,25M 24h volume), while Bio Protocol trades at Rp443.65 (market cap Rp1,01T, Rp168,57M 24h volume). The key difference: Bio Protocol is far larger — about 8269.2× FC Barcelona Fan Token's market cap, and FC Barcelona Fan Token's circulating supply is 26,5M / 40M BAR (67%) versus 2,3B / 3,3B BIO (69%) for Bio Protocol. Which is the better fit depends on your goals — on Pluang, investors hold FC Barcelona Fan Token for 57 Days and Bio Protocol for 18 Days on average.
| BAR | BIO | |
|---|---|---|
Market Cap | Rp122,14M | Rp1,01T |
Volume (24h) | Rp83,25M | Rp168,57M |
Circulating Supply | 26,5M / 40M BAR (67%) | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 57 Days | 18 Days |
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FC Barcelona Fan Token
BAR is a utility token created in collaboration between FC Barcelona and Chiliz. Token holders can become part of the community, start influencing club decisions and participate in Fan Rewards contests. The weight of the vote depends on the number of tokens that holders have, and some activities may require more than just one token. Token holders also have their own perks, including VIP access to the Camp Nou home stadium, the opportunity to meet world-famous football legends, as well as the chance to attend autograph sessions and get signed items and team merch.
Read more on BAR →About Bio Protocol
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →
